Early Phase 1
Completed N=31
Acute Effects of E-Cigarette Aerosol Inhalation
Endothelial Dysfunction · Biochemical Markers
Source: ClinicalTrials.gov NCT03479203 ↗
Enrolled (actual)
31
Serious AEs
0.0%
Results posted
May 2024
Primary outcomePrimary: Inflammatory Blood-Based Biomarkers — 5 fold change — p=0.05
Summary
This study comprises a portion of a larger study designed to compare results of vascular function in non-smokers to vascular function in healthy smokers chronically exposed to nicotinized electronic cigarette aerosol versus conventional cigarettes.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Inflammatory Blood-Based Biomarkers |
5 | 0.05 |
| PRIMARY Acute Change in Aortic Pulse Wave Velocity Post-vaping |
0.19 | — |
| PRIMARY Change in Femoral Artery Flow-Mediated Dilation Post-Vaping |
-3.20 | — |
| PRIMARY Change in Washout Time Post-Vaping |
-1.50 | — |
| PRIMARY Change in Upslope Post-Vaping |
— | — |
| PRIMARY Change in Overshoot Post-Vaping |
10 | — |
| PRIMARY Change in Breath Hold Index Post-Vaping |
-0.02 | — |
Eligibility Criteria
Inclusion Criteria
- BMI of 18.5 - 30
Exclusion Criteria
- Cancer
- HIV
- Mental illness
- Overt cardio- or neurovascular disease (prior heart attack, stroke, transient ischemic attacks)
- Serious arrhythmias
- Bronchospastic disease
- Upper respiratory tract infection within the past six weeks
- Chronic medication or antibiotics
- Claustrophobia / contraindications for MRI
Data sourced from ClinicalTrials.gov (NCT03479203). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.